| Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse … KS Siveen, N Mustafa, F Li, R Kannaiyan, KS Ahn, AP Kumar, WJ Chng, ... Oncotarget 5 (3), 634, 2014 | 157 | 2014 |
| Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat L Yao, N Mustafa, EC Tan, A Poulsen, P Singh, MD Duong-Thi, JXT Lee, ... Journal of medicinal chemistry 60 (20), 8336-8357, 2017 | 94 | 2017 |
| Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological … EG Yang, N Mustafa, EC Tan, A Poulsen, PM Ramanujulu, WJ Chng, ... Journal of medicinal chemistry 59 (18), 8233-8262, 2016 | 93 | 2016 |
| VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer S Hart, V Novotny-Diermayr, KC Goh, M Williams, YC Tan, LC Ong, ... Molecular cancer therapeutics 12 (2), 151-161, 2013 | 77 | 2013 |
| Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma MK Shanmugam, KS Ahn, JH Lee, R Kannaiyan, N Mustafa, KA Manu, ... Frontiers in pharmacology 9, 365, 2018 | 61 | 2018 |
| Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat Y Chu-Farseeva, N Mustafa, A Poulsen, EC Tan, JJY Yen, WJ Chng, ... European journal of medicinal chemistry 158, 593-619, 2018 | 45 | 2018 |
| MMSET regulates expression of IRF4 in t (4; 14) myeloma and its silencing potentiates the effect of bortezomib Z Xie, C Bi, JY Chooi, ZL Chan, N Mustafa, WJ Chng Leukemia 29 (12), 2347-2354, 2015 | 38 | 2015 |
| MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma B Li, J Yan, T Phyu, S Fan, TH Chung, N Mustafa, B Lin, L Wang, ... Blood, The Journal of the American Society of Hematology 134 (23), 2046-2058, 2019 | 32 | 2019 |
| 3-Chloro-3-methyl-2, 6-diarylpiperidin-4-ones as anti-cancer agents: synthesis, biological evaluation, molecular docking, and in silico ADMET prediction A Ramalingam, N Mustafa, WJ Chng, M Medimagh, S Sambandam, ... Biomolecules 12 (8), 1093, 2022 | 18 | 2022 |
| Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor U Soumyanarayanan, PM Ramanujulu, N Mustafa, S Haider, AHF Nee, ... European Journal of Medicinal Chemistry 184, 111755, 2019 | 18 | 2019 |
| Daratumumab efficiently targets NK/T cell lymphoma with high CD38 expression N Mustafa, HFA Nee, XTJ Lee, W Jin, Y Yu, Y Chen, J Yang, WJ Chng Blood 130 (Supplement 1), 2814-2814, 2017 | 15 | 2017 |
| Twelve tips to leverage AI for efficient and effective medical question generation: a guide for educators using Chat GPT IR Indran, P Paranthaman, N Gupta, N Mustafa Medical Teacher, 1-6, 2024 | 13 | 2024 |
| Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma N Mustafa, AHF Nee, JY Chooi, SHM Toh, TH Chung, V Selvarajan, S Fan, ... Journal for Immunotherapy of Cancer 9 (7), 2021 | 11 | 2021 |
| Biphasic activity of CD137 ligand-stimulated monocytes on T cell apoptosis and proliferation KMM Shaqireen, N Mustafa, AL Holme, S Pervaiz, H Schwarz Journal of leukocyte biology 89 (5), 707-720, 2011 | 10 | 2011 |
| VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim N Mustafa, JXT Lee, HFA Nee, C Bi, TH Chung, S Hart, WJ Chng Oncotarget 8 (60), 101847, 2017 | 7 | 2017 |
| CD55 and CD59 Can Limit the Anti-Tumor Efficacy of Daratumumab in Natural Killer/T-Cell Lymphoma N Mustafa, AHF Nee, JY Chooi, SHM Toh, YT Hee, V Selvarajan, L Zhou, ... Blood 132 (Supplement 1), 1663-1663, 2018 | 4 | 2018 |
| Molecular determinants underlying the anti-cancer efficacy of CD38 monoclonal antibodies in hematological Malignancies N Mustafa, MI Azaman, GGK Ng, WJ Chng Biomolecules 12 (9), 1261, 2022 | 3 | 2022 |
| T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival S de Mel, N Mustafa, V Selvarajan, MI Azaman, PW Jaynes, ... Plos one 17 (1), e0261469, 2022 | 1 | 2022 |
| Daratumumab Resistant Natural Killer/T-Cell Lymphoma Exhibit an Addiction to the Exosome Biogenesis Pathway for Survival N Mustafa, MI Azaman, WJ Chng Blood 138, 2256, 2021 | 1 | 2021 |
| A Novel and Highly Selective Dual PI3K/mTOR Kinase Inhibitor VS-5584, Shows Promising Therapeutic Potential For The Treatment Of Multiple Myeloma N Mustafa, S Hart, WJ Chng Blood, The Journal of the American Society of Hematology 122 (21), 4433-4433, 2013 | 1 | 2013 |
